Pre-Made Interferon Beta Biosimilar, Recombinant Protein targeting IFNAR1: Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Interferon Beta Biosimilar, Recombinant Protein targeting IFNAR1: Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Interferon beta is a cytokine in the interferon family used to treat multiple sclerosis (MS)
| Products Name (INN Index) | Pre-Made Interferon Beta Biosimilar, Recombinant Protein targeting IFNAR1: Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC |
|---|---|
| INN Name | interferon beta |
| Target | IFNAR1 |
| Format | Recombinant Protein |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IFNB1 (interferon beta 1, IFNB) *a (C38) 22-187 |
| VD LC | IFNB1 (interferon beta 1, IFNB) *a (C38) 22-187 |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Biogen,?Inc. (Cambridge MA USA) / Merck Serono?International S.A. (Geneva Switzerland) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IFNAR1 |
| Package |
